PRINCETON, N.J., May 22 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com/), an online investment newsletter focused on long- term growth and income-generating stocks, announced today that it has provided subscribers with a detailed report updating outlooks on stem cell companies including Geron (NASDAQ:GERN), Aastrom Biosciences (NASDAQ:ASTM), and ViaCell (NASDAQ:VIAC).
All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/index.php?refer=BMR240P In its report, BullMarket.com wrote: "One event in the past year had a significant impact on companies in this sector, like Geron, Aastrom Biosciences, and ViaCell, and that was the results of last November's election. These companies saw their shares increase in value as investors figured that a Congress controlled by Democrats would be more likely to increase federal funding for stem cell research. So far, there has been little movement on that front as Congress and the White House are locked in a battle over funding for the war Iraq..." BullMarket.com looked at the following topics, among others: -- What are the near-term catalysts, if any, for stem cell companies?
-- For investors interested in putting some money toward the stem cell
trend, which stock is the best bet?
-- How is the political climate shaping up with regard to stem cell
initiatives? About BullMarket.com:
Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.
NOTE: This release was published by Indie Research Advisors, LLC (CRD #131926), a registered investment advisor with the NASD and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
CONTACT: Marcie Martin, +1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC CONTACT: Marcie Martin of Indie Research Advisors, LLC, +1-888-278-5515 Web site: http://www.bullmarket.com/
|